About Sanofi
Sanofi is a publicly listed company based in Paris (France) founded in 1973 by Jean Rene Sautier, and was acquired by Beximco Pharma in September 2021. It operates as a pharmaceutical and nutraceutical products are developed across seven therapeutic areas. It operates on a AI-as-a-Service, Professional Services, and HealthTech model. Sanofi has completed 32 acquisitions, including Ablynx, Amunix and BMP Sunstone. Its chief executive is Paul Hudson. Its website sanofi.com draws about 878 thousand monthly visits. Its Indian entity Sanofi Healthcare India Private Limited reported revenue of ₹1,726 Cr. Sanofi offers products and services including Vaccines, Medicines, and Consumer Healthcare (Opella). Its focus areas include Pharmaceuticals, Biopharmaceuticals, Biotechnology and Vaccines. Its competitors include Merck, Roivant Sciences, AbbVie, Gilead and Lilly and 5 more; 2 of its 10 listed competitors have raised funding.
Company details
Sanofi is established as a biopharmaceutical company focused on research and development, leveraging artificial intelligence to innovate healthcare solutions. The company is engaged in multiple therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, and vaccines. Operations are supported by advanced technology platforms and clinical trials to develop new treatments. Sanofi is committed to sustainable healthcare access and environmental impact reduction. Partnerships and external innovation are pursued globally across North America, Europe, and China to enhance its offerings. The companys pipeline includes 82 compounds in clinical development and 24 trials in phase 3, targeting improved health outcomes.
- Headquarters Paris, France
- Founders Jean Rene Sautier
- Stage Public
- SectorsHealthcare
- Website category Health
- Email••••••••
- Phone•••• ••••
- Website sanofi.com/en
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Beximco Pharma (Sep 2021)
- Legal Name Sanofi
- Date of Incorporation 10 Mar, 1993
- Annual Revenue₹1,726 Cr
FY 2025 · -18% YoY
- Net Profit₹1,662 Cr
FY 2025 · 96% margin
- EBITDA₹2,054 Cr
FY 2025 · 119% margin
- InvestorsBlackstone
& 8 more
- Investments & AcquisitionsAblynx
& 31 more
- Acquired byBeximco Pharma
(Sep 2021)
Associated legal entities of Sanofi
Sanofi operates through Sanofi Healthcare India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sanofi Healthcare India Private Limited CIN U24110MH1993PTC332584 | Active | 10 Mar 1993 | Mumbai, Maharashtra | ₹1,726 Cr | 1,076 | 4 | View details |
Products & Services of Sanofi
Sanofi offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and Consumer Healthcare (Opella).
Vaccines are developed for infectious disease prevention.
Medicines are provided for various therapeutic areas.
Consumer healthcare products are offered for daily wellness.
Apps and channels of Sanofi
its YouTube channel Sanofi has 33K subscribers and 30 videos.
Videos from Sanofi
The most watched videos on Sanofi's YouTube channel, Sanofi (33K subscribers). Click a video to play it here.
More on Sanofi.
Funding Insights of Sanofi
- Total Rounds 16
- First Round $1.63M
(May 2009)
- Investors Count 8
Latest 10 of 16 funding rounds of Sanofi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | – | Post-IPO | – | – | |
| Jun 2022 | – | Grant | – | – | |
| Mar 2022 | $329.11M | Post-IPO | – | – | |
| Jan 2021 | $81,935 | Grant | – | – | |
| Aug 2020 | – | Grant | – | – | |
| Feb 2017 | $436,344 | Grant | – | – | |
| Jan 2017 | – | Grant | – | – | |
| Sep 2016 | $43.2M | Grant | – | – | |
| Mar 2016 | $88,063 | Grant | – | – | – |
| Jan 2016 | $359,502 | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Sanofi
Sanofi has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, Gates Foundation and Beximco Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Provides banking accounts, loans, credit cards, and digital services for individuals and businesses. | 1892 | anb.com | Amarillo, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Government entity focused on information and services | 2000 | usa.gov | United States | |
- | – | phe.gov | - | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
- | – | noaa.gov | - | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States | |
Generic pharmaceuticals are manufactured for domestic and international markets. | 1976 | beximcopharma.com | Dhaka, Bangladesh |
Investor details for Sanofi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sanofi Healthcare India Private Limited (Sanofi)
Sanofi Healthcare India Private Limited is the primary company behind Sanofi. The board of Sanofi Healthcare India Private Limited currently have 3 directors; the longest-serving is Saravanan Devarajan, appointed in 2022. 35 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saravanan Devarajan DIN 09557725 | Whole-time director | 01 Apr 2022 | 4 yrs 6 mo | Sanofi Healthcare India Private Limited |
| Somak Ghosh DIN 10802672 | Additional Director | 13 Nov 2024 | 1 yr 11 mo | Sanofi Healthcare India Private Limited |
| Mayur Dinesh Shah DIN 10812242 | Additional Director | 13 Nov 2024 | 1 yr 11 mo | Sanofi Healthcare India Private Limited |
People of Sanofi
637 people are tracked at Sanofi (367 in leadership, 14 in board & advisors, 256 in team).
| Name | Role | Group |
|---|---|---|
Jean Rene Sautier | Founder | Leadership |
Paul Hudson | CEO | Leadership |
Mikhael Aboukrat | Head Of Service Management & C2r | Leadership |
Edouard Clavel | Finance Business Partner Vaccines France | Leadership |
Kristin Breitschopf | Head Of Immunology & Inflammation Research Program Management, Portfolio Innovation And Excellence | Leadership |
Lavesh Gwalani | Immunology Group Head - Principal Scientist, Gene Therapy Immunology | Leadership |
Bernadette Wang | Senior Director, Head, US Public Affairs And Patient Advocacy, Neurology | Leadership |
Jim Tartaglia | VP R&d; Head Of New Vaccine Strategy And Execution | Leadership |
Kei Takada | Head Of RSV Franchise, Vaccines Business Unit | Leadership |
Marie-Helene Chassagne | Head Of Reward And Performance EMEA And Global Corporate Functions | Leadership |
Dumont Stephanie | Executive Assistant To The Chief Quality Officer | Leadership |
Lisa Barbieri Moher | Head Of North America Distribution Package Engineering And Graphics | Leadership |
Ina Vannijvel | Digital Transformation, Program Director And Change Coach | Leadership |
Ivana Silli | Partner Markets Europe & Eurasia Quality Manager At Sanofi | Leadership |
Mathias Ganz | ITS Business Partner | Leadership |
Luis Barreto | Vice President, Immunization And Science Policy | Leadership |
Uday Sheth | Head Of Digital Gbus Agile & Service Excellence | Leadership |
Dominika Kovacs | General Manager, US Respiratory Franchise Speciality Care | Leadership |
Bastian Frehse | Country CFO | Leadership |
Okan Güner | Vaccines Head Of Business Planning Eurasia | Leadership |
617 more people are available in the full profile.
Complete people profiles for Sanofi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sanofi
Sanofi is a publicly listed company on the ASX with ticker symbol BIT in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jul 2002
- Listed onNASDAQ: SNY
- Listed entityBIOTRON LIMITED
- Exchange sectorHealth technology
Financials of Sanofi
Figures of Sanofi Healthcare India Private Limited, the primary company behind Sanofi, for FY 2025. Revenue was ₹1,726 Cr (-18% year on year). Net profit was ₹1,662 Cr (96% margin). EBITDA was ₹2,054 Cr (119% margin). Revenue has grown at a compounded annual rate of -3% over three years and -1% over five years.
- ₹1,726 CrRevenue · FY 2025 · -18% YoY
- ₹1,662 CrNet profit · 96% margin
- ₹2,054 CrEBITDA · 119% margin
- ₹44.14 CrPaid-up capital
- 1,076Employees (provident fund records)
- -3%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Sanofi Healthcare India Private Limited are on its company page.
Detailed financial statements for Sanofi
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sanofi
Sanofi has strategically engaged in corporate development activities, having acquired 32 companies. Notable acquisitions include Ablynx, Amunix and BMP Sunstone.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A biopharmaceutical company focused on developing novel vaccines. | dynavax.com | Berkeley, United States | 1996 | Dec 2025 | •••• | |
Vicebio is focused on respiratory disease prevention through innovative vaccines. | vicebio.com | London, United Kingdom | 2019 | Jul 2025 | $1.15B | |
Selective kinase inhibitors are developed for genomically defined cancers. | blueprintmedicines.com | Cambridge, United States | 2008 | Jun 2025 | $9.1B | |
Bispecific antibodies for B cell cancer treatment are developed. | dr0201.tcc.mode | – | 0 | May 2025 | •••• | |
Microglia-focused therapeutics for neurodegenerative diseases are developed. | vigilneuro.com | Cambridge, United States | 2020 | May 2025 | $470M | |
Antibody-based immunotherapeutics are developed for cancer and infectious diseases. | inhibrx.com | Solana Beach, United States | 2009 | Jan 2024 | $2.2B | |
Natural dietary supplements with CoQ10, curcumin, and vitamins are provided. | qunol.com | Montville, United States | 2006 | Jul 2023 | •••• | |
Investigational immunomodulatory therapies for immune-mediated diseases are developed. | proventionbio.com | Hunterdon, United States | 2016 | Mar 2023 | •••• | |
Peptide-based therapeutics are developed for cancers and immune disorders. | amunix.com | Mountain View, United States | 2006 | Dec 2021 | •••• | |
Biotech company focused on antigen and drug target discovery for prevention and treatment of dermatological/infectious conditions | origimm.com | Vienna, Austria | 2014 | Dec 2021 | •••• |
Complete acquisition details for Sanofi
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sanofi
15 dated milestones of Sanofi across 52 years, from founding to its latest funding, stage changes and deals.
- Founded Sanofi is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.6M.
- Exit Acquired by Beximco Pharma.
- Acquisition Acquires Origimm.
- Acquisition Acquires Amunix.
- Acquisition Acquires Provention Bio.
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires Qunol.
- Acquisition Acquires Inhibrx.
- Acquisition Acquires Vigil Neuroscience.
- Acquisition Acquires DR-0201.
- Acquisition Acquires Blueprint Medicines.
- Acquisition Acquires Vicebio.
- Acquisition Acquires Dynavax Technologies.
Competitors of Sanofi
Sanofi has 10 listed competitors in our database, 2 of them funded. They include Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Sanofi
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sanofi
The website of Sanofi (sanofi.com) receives about 878.5K visits a month and ranks #76,545 among all websites worldwide, #2,164 in Health.
- Monthly visits878.5K
▲ 29.3% vs previous month
- Unique visitors330.5K
per month
- Global rank#76,545
among all websites
- Category rank#2,164
Health · Health
- Bounce rate47%
- Pages per visit2.6
- Average visit1 min 38 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with Sanofi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sanofi-aventis.co.uk | sanofi-aventis.co.uk | 100% | – | – | – |
| pfizer.com | 98% | 1.9M | #24,984 | View details | |
| clinicaltrials.gov | 95% | 3.3M | #13,034 | View details | |
| gsk.com | 91% | 1.3M | #56,834 | View details | |
| novonordisk.com | 90% | 637.8K | #83,485 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Sanofi
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Sanofi (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sanofi
Complete news archive for Sanofi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sanofi
Sanofi was founded in 1973 and raised its 1st funding round 36 years after it was founded.
Sanofi is headquartered in Paris, France.
Paul Hudson is the current CEO of Sanofi.
The primary company behind Sanofi, Sanofi Healthcare India Private Limited, reported revenue of ₹1,726 Cr for FY 2025, down 18% year on year.
Sanofi is established as a biopharmaceutical company focused on research and development, leveraging artificial intelligence to innovate healthcare solutions. The company is engaged in multiple therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, and vaccines. Operations are supported by advanced technology platforms and clinical trials to develop new treatments. Sanofi is committed to sustainable healthcare access and environmental impact reduction. Partnerships and external innovation are pursued globally across North America, Europe, and China to enhance its offerings. The companys pipeline includes 82 compounds in clinical development and 24 trials in phase 3, targeting improved health outcomes.
Sanofi's top competitors include Merck, Roivant Sciences and AbbVie.
Sanofi offers Vaccines, Medicines, and Consumer Healthcare (Opella).
Yes, Sanofi is publicly traded on ASX under the ticker symbol BIT.
Sanofi has made 32 acquisitions, including Ablynx, Amunix, and BMP Sunstone.
Sanofi has 9 investors. Key investors include Blackstone, Gates Foundation, Beximco Pharma, European Union, and USAGov.
Sanofi operates through Sanofi Healthcare India Private Limited.
Yes. Sanofi was acquired by Beximco Pharma in September 2021.